Pharma & Metabolic Health
Eli Lilly raises forecast on continued GLP-1 demand
By Intent.Health Team • April 30, 2026
What’s happening
Eli Lilly and Company raised its full-year forecast, driven by strong demand for its weight-loss and diabetes drugs.
What’s changing / Business impact
-
GLP-1 drugs continue to dominate: obesity and diabetes markets.
-
High demand offsets pricing pressure.
-
Strengthens Lilly’s position in the fastest-growing drug category.
Why this matters
GLP-1 demand is one of the largest demand shifts in U.S. healthcare today.
This shows:
-
Obesity treatment is becoming a major revenue driver.
-
Demand remains strong despite: pricing pressure and regulatory scrutiny.
-
Pharma growth is increasingly tied to metabolic disease markets.